RLMD News and Press, Relmada Therapeutics Inc. From 02/23/21

Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference PR Newswire NEW YORK , Feb. 23, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the ce...

Relmada Therapeutics ([[RLMD]] -2.1%) has enrolled first patient in first Phase 3 trial (RELIANCE I) evaluating its lead product candidate, REL-1017, as an adjunctive treatment for major depressive disorder. Topline data is expected in 1H of 2022.Primary endpoint will be the change from basel...

Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder NEW YORK , Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addres...

Relmada Therapeutics to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, Nov. 17, 2020 NEW YORK , Nov. 17, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the ...

Gainers: Miragen Therapeutics (MGEN) +86%, Titan Pharmaceuticals (TTNP) +62%, Community Health Systems (CYH) +35%, Scholar Rock Holding (SRRK) +7%, Rafael Holdings (RFL) +7%.Losers: Neovasc (NVCN) -44%, Akerna (KERN) -19%, Tiziana Li...

Relmada Therapeutics ([[RLMD]] -1.4%) has expanded its leadership team with appointments of Dr. Paolo Manfredi, M.D., as acting Chief Scientific Officer and Marco Pappagallo, M.D., as acting Chief Medical Officer ((CMO)).Dr. Pappagallo most recently served as CMO at CerSci Therapeut...

Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Actin...

NEW YORK , July 13, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced that effective as of market open on July 14, 2020 , its common stock has been appr...

Three of the best-performing pharmaceutical stocks over the past year have been clinical-stage biotech and biopharmaceutical companies -- businesses that aren't making profits but have promising drugs, or more often, drug candidates. Though a few candidates will become breakout successes, the o...

The following slide deck was published by Relmada Therapeutics, Inc. in conjunction with this Read more ...